These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 30231891)

  • 21. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users.
    Witt DM; Delate T; Clark NP; Martell C; Tran T; Crowther MA; Garcia DA; Ageno W; Hylek EM;
    J Thromb Haemost; 2010 Apr; 8(4):744-9. PubMed ID: 20398186
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quality of anticoagulation with warfarin across Kuwait.
    Zubaid M; Saad H; Ridha M; Mohanan Nair KK; Rashed W; Alhamdan R; Alenezi F; Maghami M; Sadek A
    Hellenic J Cardiol; 2013; 54(2):102-6. PubMed ID: 23557609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study.
    Dentali F; Pignatelli P; Malato A; Poli D; Di Minno MN; Di Gennaro L; Rancan E; Pastori D; Grifoni E; Squizzato A; Siragusa S; Di Minno G; Ageno W
    Am J Hematol; 2012 Apr; 87(4):384-7. PubMed ID: 22367852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin.
    Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J
    Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
    Hylek EM; Go AS; Chang Y; Jensvold NG; Henault LE; Selby JV; Singer DE
    N Engl J Med; 2003 Sep; 349(11):1019-26. PubMed ID: 12968085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A retrospective review of clinical international normalized ratio results and their implications.
    Kassab MM; Radmer TW; Glore JW; Visotcky A; Robertson J; Degroot B
    J Am Dent Assoc; 2011 Nov; 142(11):1252-7. PubMed ID: 22041410
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delayed discharges due to initiation of warfarin in atrial fibrillation: a prospective audit.
    Tan ES; Bonnett TJ; Abdelhafiz AH
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):232-5. PubMed ID: 17996662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Feasibility of Extended-interval Follow-up for Patients Receiving Warfarin.
    Carris NW; Spinelli A; Pierini D; Taylor JR; Anderson KV; Sando K; Powell J; Rosenberg EI; Zumberg MS; Smith SM; Gums JG; Dietrich E
    Cardiovasc Ther; 2015 Jun; 33(3):98-103. PubMed ID: 25786578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Better stability of acenocoumarol compared to warfarin treatment in one-year observational, clinical study in patients with nonvalvular atrial fibrillation.
    Kulo A; Kusturica J; Kapić E; Becić F; Rakanović-Todić M; Burnazović-Ristić L; Mehmedović A; Lepar O; Mulabegović N
    Med Glas (Zenica); 2011 Feb; 8(1):9-14. PubMed ID: 21263388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population.
    Currie CJ; McEwan P; Emmas C; Morgan CL; Peters JR
    Curr Med Res Opin; 2005 Dec; 21(12):1905-13. PubMed ID: 16368039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of pharmacist-managed oral anticoagulation therapy in older veterans.
    Poon IO; Lal L; Brown EN; Braun UK
    J Clin Pharm Ther; 2007 Feb; 32(1):21-9. PubMed ID: 17286786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population.
    Jones M; McEwan P; Morgan CL; Peters JR; Goodfellow J; Currie CJ
    Heart; 2005 Apr; 91(4):472-7. PubMed ID: 15772203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation control quality affects the D-dimer levels of atrial fibrillation patients.
    Nakatani Y; Mizumaki K; Nishida K; Hirai T; Sakabe M; Oda Y; Joho S; Fujiki A; Nozawa T; Inoue H
    Circ J; 2012; 76(2):317-21. PubMed ID: 22185714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
    Laliberté F; Pilon D; Raut MK; Nelson WW; Olson WH; Germain G; Schein JR; Lefebvre P
    Curr Med Res Opin; 2014 Apr; 30(4):645-53. PubMed ID: 24256067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients.
    Blich M; Gross B
    Int J Cardiol; 2004 Jul; 96(1):89-95. PubMed ID: 15203266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation.
    Deitelzweig S; Evans M; Hillson E; Trocio J; Bruno A; Tan W; Lingohr-Smith M; Singh P; Lin J
    Curr Med Res Opin; 2016; 32(1):87-94. PubMed ID: 26451675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonadherence with INR monitoring and anticoagulant complications.
    Witt DM; Delate T; Clark NP; Garcia DA; Hylek EM; Ageno W; Dentali F; Crowther MA
    Thromb Res; 2013 Aug; 132(2):e124-30. PubMed ID: 23800635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.
    Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
    Clin Ther; 2015 Mar; 37(3):554-62. PubMed ID: 25749196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.
    Deerhake JP; Merz JC; Cooper JV; Eagle KA; Fay WP
    J Thromb Thrombolysis; 2007 Apr; 23(2):107-13. PubMed ID: 17221327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Anticoagulation and electrical cardioversion of chronic atrial fibrillation: proposal for an abbreviated protocol].
    Antonielli E; Pizzuti A; Gandolfo N; Sclavo M; Tanga M; Riva G; Leonardi G; Bassignana A; Di Leo M
    G Ital Cardiol; 1997 Aug; 27(8):803-10. PubMed ID: 9312508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.